companydata.dkcompanydata.dk

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: Financial statements 2014

CVR: 32323502

Source: annual report 2014, Danish Business Authority

01/01/2014 – 31/12/2014

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S (CVR 32323502) has filed annual accounts for 2014. In 2014, the company reported a gross profit of EUR 5,456,890 and a net result of EUR 5,786,449 compared with DKK 16,254,792 the year before. That is a decrease of 70.5% compared with the year before. Equity in the 2014 report amounted to EUR 5,250,852. The solvency ratio was 39.9%.

Gross Profit
EUR 5,456,890
Profit/Loss
EUR 5,786,449
Equity
EUR 5,250,852
Total Assets
EUR 13,161,594

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2014-5.5M EUR5.8M EUR5.3M EUR-
2013-18.5M16.3M19.1M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2014

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: The 2013 annual report is outJun 3, 2014

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2013. Gross profit came to DKK 18,483,731, and the net result was DKK 16,254,792.

About ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ACP 30.06.2012 1 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 5,567,000 and a net result of EUR -5,238,000 compared with EUR 5,001,000 the year before. Equity in the 2025 report amounted to EUR -38,639,000.

Source: annual report 2025, Danish Business Authority